Metaclipse Therapeutics is a preclinical stage biotech company developing novel cancer therapies that are tailored to each patient and their specific tumor. The Company’s first ‘personalized’ cancer therapy is for triple negative metastatic breast cancer. Metaclipse intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing their safety and effectiveness in early clinical trials by year-end 2019.
View Top Employees from Metaclipse Therapeutics Corporation| Website | http://metaclipsetherapeutics.com |
| Revenue | $1 million |
| Employees | 7 (7 on RocketReach) |
| Founded | 2012 |
| Address | 3175 Presidential Dr, Atlanta, Georgia 30303, US |
| Phone | (404) 380-1342 |
| Technologies |
JavaScript,
HTML,
PHP
+12 more
(view full list)
|
| Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Medical, Health Care, Therapeutics |
| Competitors | Batu Biologics, Inc., Etubics, Immunomic Therapeutics, Inc., UbiVac |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325414 Companies, NAICS Code 3254 Companies |
Looking for a particular Metaclipse Therapeutics Corporation employee's phone or email?
Metaclipse Therapeutics Corporation Questions
The Metaclipse Therapeutics Corporation annual revenue was $1 million in 2024.
Michael Coleman is the CEO of Metaclipse Therapeutics Corporation.
7 people are employed at Metaclipse Therapeutics Corporation.
Metaclipse Therapeutics Corporation is based in Atlanta, Georgia.
The NAICS codes for Metaclipse Therapeutics Corporation are [325, 32541, 32, 325414, 3254].
The SIC codes for Metaclipse Therapeutics Corporation are [28, 283].
Top Metaclipse Therapeutics Corporation Employees
-
35
-
55+
-
45
Related Companies
